GHRS vs. GSK

Last updated Apr 1, 2026

Compare and contrast key facts about GH Research PLC (GHRS) and GlaxoSmithKline plc (GSK).

Performance

GHRS vs. GSK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in GH Research PLC (GHRS) and GlaxoSmithKline plc (GSK). The values are adjusted to include any dividend payments, if applicable.

GHRS vs. GSK - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
GHRS GH Research PLC	10.71%	81.43%	20.69%	-40.33%	-58.34%	21.19%
GSK GlaxoSmithKline plc	13.45%	51.23%	-5.14%	9.71%	-33.41%	13.65%

Fundamentals

Market Cap GHRS : $872.13M GSK : $112.75B
EPS GHRS : -$0.78 GSK : $2.78
PB Ratio GHRS : 3.12 GSK : 6.90
Total Revenue (TTM) GHRS : $0.00 GSK : $31.95B
Gross Profit (TTM) GHRS : -$177.00K GSK : $23.18B
EBITDA (TTM) GHRS : -$50.45M GSK : $11.62B

Returns By Period

In the year-to-date period, GHRS achieves a 10.71% return, which is significantly lower than GSK's 13.45% return.

GHRS

• 1D: 7.90%
• 1M: -5.32%
• YTD: 10.71%
• 6M: -1.68%
• 1Y: 27.47%
• 3Y*: 20.73%
• 5Y*: —
• 10Y*: —

GSK

• 1D: 1.77%
• 1M: -6.66%
• YTD: 13.45%
• 6M: 30.03%
• 1Y: 48.15%
• 3Y*: 20.43%
• 5Y*: 8.75%
• 10Y*: 5.74%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

GHRS vs. GSK — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GHRS

GHRS Risk / Return Rank: 56
GHRS Sharpe Ratio Rank: 54
GHRS Sortino Ratio Rank: 58
GHRS Omega Ratio Rank: 55
GHRS Calmar Ratio Rank: 58
GHRS Martin Ratio Rank: 54

GSK

GSK Risk / Return Rank: 85
GSK Sharpe Ratio Rank: 88
GSK Sortino Ratio Rank: 84
GSK Omega Ratio Rank: 81
GSK Calmar Ratio Rank: 88
GSK Martin Ratio Rank: 85

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GHRS vs. GSK - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for GH Research PLC (GHRS) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	GHRS	GSK	Difference
Sharpe ratio Return per unit of total volatility	0.35	1.70	-1.35
Sortino ratio Return per unit of downside risk	1.10	2.30	-1.19
Omega ratio Gain probability vs. loss probability	1.13	1.29	-0.16
Calmar ratio Return relative to maximum drawdown	0.69	3.25	-2.57
Martin ratio Return relative to average drawdown	1.13	7.56	-6.44
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

GHRS vs. GSK - Sharpe Ratio Comparison

The current GHRS Sharpe Ratio is 0.35, which is lower than the GSK Sharpe Ratio of 1.70. The chart below compares the historical Sharpe Ratios of GHRS and GSK, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	GHRS	GSK	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.35	1.70	-1.35
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.36	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.25	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.07	0.33	-0.40

Correlation

The correlation between GHRS and GSK is 0.03, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

GHRS vs. GSK - Dividend Comparison

GHRS has not paid dividends to shareholders, while GSK's dividend yield for the trailing twelve months is around 3.19%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
GHRS GH Research PLC	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
GSK GlaxoSmithKline plc	3.19%	3.42%	4.60%	3.75%	5.47%	4.99%	5.59%	4.35%	5.65%	5.83%	6.86%	5.93%

Drawdowns

GHRS vs. GSK - Drawdown Comparison

The maximum GHRS drawdown since its inception was -81.15%, which is greater than GSK's maximum drawdown of -55.70%. Use the drawdown chart below to compare losses from any high point for GHRS and GSK.

Drawdown Indicators

	GHRS	GSK	Difference
Max Drawdown Largest peak-to-trough decline	-81.15%	-55.70%	-25.45%
Max Drawdown (1Y) Largest decline over 1 year	-39.49%	-14.80%	-24.69%
Max Drawdown (5Y) Largest decline over 5 years	—	-50.10%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-50.10%	—
Current Drawdown Current decline from peak	-49.61%	-9.07%	-40.54%
Average Drawdown Average peak-to-trough decline	-53.82%	-18.90%	-34.92%
Ulcer Index Depth and duration of drawdowns from previous peaks	24.06%	6.37%	+17.69%

Volatility

GHRS vs. GSK - Volatility Comparison

GH Research PLC (GHRS) has a higher volatility of 18.36% compared to GlaxoSmithKline plc (GSK) at 7.26%. This indicates that GHRS's price experiences larger fluctuations and is considered to be riskier than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GHRS	GSK	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.36%	7.26%	+11.10%
Volatility (6M) Calculated over the trailing 6-month period	55.87%	19.71%	+36.16%
Volatility (1Y) Calculated over the trailing 1-year period	78.87%	28.43%	+50.44%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	87.36%	24.74%	+62.62%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	87.36%	22.72%	+64.64%

Financials